Clover Health (CLOV) legal chief sells 51,700 shares under 10b5-1 plan
Rhea-AI Filing Summary
Clover Health Investments, Corp. Chief Legal Officer Karen Soares sold 51,700 shares of Class A Common Stock on July 20, 2026, reported as a sale in the open market or a private transaction at a $4.51 weighted average price, with individual prices from $4.46 to $4.59, pursuant to a 10b5-1 plan adopted on March 13, 2026. Following this sale, she directly holds 1,505,522 shares.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 51,700 shares
Net Sell
1 txn
Insider
Soares Karen
Role
Chief Legal Officer
Sold
51,700 shs ($233K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Class A Common Stock F1, F2 | 51,700 | $4.51 | $233K |
Holdings After Transaction:
Class A Common Stock — 1,505,522 shares (Direct)
Footnotes (2)
- F1. The sales reported in this Form 4 were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on March 13, 2026.
- F2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.46 to $4.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
Key Figures
Shares sold: 51,700 shares
Weighted average sale price: $4.51 per share
Sale price range: $4.46 to $4.59 per share
+1 more
4 metrics
Shares sold
51,700 shares
Class A Common Stock sold on July 20, 2026
Weighted average sale price
$4.51 per share
Average price for the 51,700 shares sold
Sale price range
$4.46 to $4.59 per share
Range of prices for multiple sale transactions
Shares held after transaction
1,505,522 shares
Direct ownership following the July 20, 2026 sale
Key Terms
10b5-1 plan, weighted average price, Class A Common Stock
3 terms
10b5-1 plan regulatory
"The sales reported in this Form 4 were effected pursuant to a 10b5-1 plan"
A 10b5-1 plan is a pre-arranged strategy that allows company insiders to buy or sell their shares at predetermined times and prices, even while they are aware of confidential information. It acts like a scheduled appointment for trading, helping ensure transactions happen transparently and legally, which can reassure investors that trades are not based on insider knowledge.
weighted average price financial
"The price reported in column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Class A Common Stock financial
"security_title: Class A Common Stock"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did CLOV report for Karen Soares?
Clover Health Investments, Corp. reported that Chief Legal Officer Karen Soares sold 51,700 shares of Class A Common Stock on July 20, 2026. The transaction was reported as a sale in the open market or a private transaction under a pre-arranged 10b5-1 plan adopted on March 13, 2026.
At what prices did Karen Soares sell CLOV Class A Common Stock?
Karen Soares’ sale of CLOV Class A Common Stock had a $4.51 weighted average price per share. According to the disclosure, the shares were sold in multiple transactions at prices ranging from $4.46 to $4.59 per share, inclusive, on July 20, 2026.
Was the CLOV insider sale by Karen Soares under a 10b5-1 plan?
Yes, the sales reported for CLOV by Karen Soares were effected pursuant to a 10b5-1 plan. The filing states that this pre-arranged trading plan was adopted by the reporting person on March 13, 2026, and the Rule 10b5-1 checkbox was affirmatively marked.
What type of security did Karen Soares trade in the CLOV Form 4?
Karen Soares traded Class A Common Stock of Clover Health Investments, Corp. The Form 4 reports a single non-derivative transaction, identified with the code “S” for a sale, covering 51,700 shares at a weighted average price of $4.51 per share.